Equity Field Notes from temporal sources

[DanWebzster]

SCYX ( the stock and the fungal superbug)

Presently there are only 9 FDA-approved antifungals .

The most recently approved antifungal is an azole marketed by ALPMY in the U.S. and PFE in Europe. First year revs in USA were $53mn. PFE paid 70mn (+ $427mn in potential milestones) for European rights.

GILD's antifungal of last resort produced revs of $366mn in 2017.

SCY-078 is a semi-synthetic derivative of a compound found in Juniper.

Data from a Ph2B trial in vaginal candidiasis will read out 7/18.

SCY-078 has a clinical hold on its IV formulation for invasive candidiasis.

SCY-078 may provide an opty for licensing to regions outside of the USA for the emerging fungal superbug, C. Auris.

3/31/18 SCYX had $63.7mn in cash and $10mn in debt.


Emergence of the Fungal Superbug

The theory that dinosaurs may have been wiped out by a fungal infection has been gaining credence.

In 2009 C. Auris was first identified in an ear canal in Japan. Since then it has been found in many countries. In 2013, it was first found in the USA.

C. Auris is unique in that it is a fungus that acts like a bacterium. Some now recognize it as the first fungal Superbug.